Form 4: Kymera Director Sells All Shares After Option Exercise

Kymera Therapeutics Director Pamela Esposito exercised stock options and subsequently sold all resulting common shares, as detailed in a Rule 10b5-1 plan.

Summary

• Pamela Esposito, a Director at Kymera Therapeutics, Inc. (KYMR), executed a series of transactions on December 17, 2025, under a pre-arranged Rule 10b5-1 trading plan dated September 17, 2025.
• Esposito exercised stock options to acquire a total of 27,563 shares of common stock.
• The options exercised included 12,563 shares at an exercise price of $49.1, 12,000 shares at $27.67, and 3,000 shares at $31.2.
• Immediately following the option exercises, Esposito sold all 27,563 shares of common stock acquired.
• The sales were executed at weighted average prices ranging from $81.557 to $84.07.
• After these transactions, Pamela Esposito's direct beneficial ownership of Kymera Therapeutics common stock is 0 shares.
• Esposito retains beneficial ownership of 7,500 stock options with an exercise price of $49.1 and 13,000 stock options with an exercise price of $31.2, all of which are fully vested and exercisable.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the transactions were pre-planned under a Rule 10b5-1 plan, the complete liquidation of direct common stock holdings by a director, even if for personal liquidity, can be perceived as a lack of strong conviction by some investors. However, it does not reflect on the company's operational performance.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned liquidity management rather than a reaction to immediate company news.
• The exercise of options at significantly lower prices ($27.67, $31.2, $49.1) compared to the sale prices (ranging from $81.557 to $84.07) indicates a profitable liquidity event for the director.

Negatives

• The director sold all common shares acquired through option exercises, resulting in zero direct beneficial ownership of common stock.
• A director reducing their direct equity stake to zero, even if pre-planned, could be interpreted by some investors as a lack of long-term conviction, although it is a common personal liquidity event.

Risks

• No specific risks related to the company's operations or financial health were mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as option exercises and subsequent share sales, are common in the biotechnology and pharmaceutical industries, particularly for directors and executives managing personal liquidity or diversifying their portfolios. The use of a Rule 10b5-1 plan is a standard practice to execute such transactions in compliance with insider trading regulations.

Comparison to Industry Standards

• Insider selling, especially a full liquidation of shares acquired through options, is a common occurrence across industries for personal financial planning, diversification, or tax purposes.
• The execution of these transactions under a Rule 10b5-1 plan aligns with best practices for corporate governance, providing transparency and mitigating concerns about trading on material non-public information.
• While the complete sale of directly held common stock might be noted by investors, it does not inherently signal a negative outlook for Kymera Therapeutics when viewed in the context of a pre-planned liquidity event, unlike unscheduled, large-scale selling by multiple insiders.

Corporate Governance

Stakeholder Impact

• Shareholders: May note the director's decision to reduce direct equity exposure to zero, potentially influencing sentiment, though the pre-planned nature mitigates immediate concerns.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The director's transactions, while resulting in zero direct beneficial ownership of common stock, were executed under a pre-arranged Rule 10b5-1 trading plan. This suggests a planned liquidity event rather than a reaction to new negative information. Investors should consider the company's broader financial health and strategic outlook rather than solely this insider transaction. Without additional fundamental news, a 'hold' recommendation is appropriate as this event alone does not warrant a strong change in investment thesis.

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Options, Share Sale, Pamela Esposito, Rule 10b5-1, Director Transactions